משרד הבריאות מחזיר בדחיפות תרופה מסוכנת - הפרטים

הערכה

The Health Ministry is pulling IMAAVY from Israeli hospitals and clinics after Johnson & Johnson, the distributor, flagged a manufacturing risk: glass particles in certain batches. This is a level-two recall, meaning the affected lots must be isolated and returned to SLA for a credit. The drug treats generalized myasthenia gravis in adults and teens 12 and older with specific antibodies. For patients on this therapy, the immediate concern is continuity of treatment, since a recall doesn't come with a substitute. Watch for which batch numbers are affected and how quickly the ministry or distributor offers an alternative supply.